Vigil Neuroscience, Inc.
DelistedCIK 1827087fmd_1ACDESX60XS00ER08Q1YGW5C1MManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2021 to Jun 30, 2025, 18 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
| Realized investment gains (losses) | – | – | 0 | 0 |
| Research and development | 32 | 47 | 61 | 62 |
| Total operating expenses | 42 | 69 | 89 | 90 |
| Operating income | (42) | (69) | (89) | (90) |
| Interest and investment income | 0 | 1 | 6 | 5 |
| Other non-operating income (expense) | (1) | 1 | 6 | 5 |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | (43) | (68) | (83) | (84) |